Their findings reveal that IL-27 enhances the persistence and effector functions of tumor-infiltrating CD8+ T lymphocytes (TILs), preventing exhaustion, sustaining T cell-dependent tumor control and immunotherapy efficacy without significant systemic side effects. The gene discussed is CD8A; the disease is neoplasm.